Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E Past Earnings Performance
Past criteria checks 1/6
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E has been growing earnings at an average annual rate of 22.2%, while the Pharmaceuticals industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 18% per year. Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E's return on equity is 14.3%, and it has net margins of 11.6%.
Key information
22.2%
Earnings growth rate
21.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 9.8% |
| Revenue growth rate | 18.0% |
| Return on equity | 14.3% |
| Net Margin | 11.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,922 | 223 | 466 | 0 |
| 30 Sep 23 | 1,779 | 226 | 443 | 0 |
| 30 Jun 23 | 1,615 | 221 | 413 | 0 |
| 31 Mar 23 | 1,533 | 224 | 397 | 0 |
| 31 Dec 22 | 1,484 | 229 | 382 | 0 |
| 30 Sep 22 | 1,487 | 254 | 349 | 0 |
| 30 Jun 22 | 1,420 | 229 | 334 | 0 |
| 31 Mar 22 | 1,321 | 207 | 310 | 0 |
| 31 Dec 21 | 1,246 | 166 | 303 | 0 |
| 30 Sep 21 | 1,140 | 136 | 283 | 0 |
| 30 Jun 21 | 1,060 | 115 | 273 | 0 |
| 31 Mar 21 | 1,010 | 106 | 267 | 0 |
| 31 Dec 20 | 960 | 97 | 260 | 0 |
| 30 Sep 20 | 947 | 119 | 253 | 0 |
| 30 Jun 20 | 947 | 105 | 230 | 0 |
| 31 Mar 20 | 921 | 94 | 209 | 0 |
| 31 Dec 19 | 894 | 82 | 189 | 0 |
| 30 Sep 19 | 853 | 85 | 172 | 0 |
| 30 Jun 19 | 815 | 90 | 172 | 0 |
| 31 Mar 19 | 810 | 110 | 165 | 0 |
| 31 Dec 18 | 806 | 129 | 157 | 0 |
| 31 Dec 17 | 628 | 89 | 120 | 0 |
| 31 Dec 16 | 382 | 27 | 97 | 0 |
| 31 Dec 15 | 278 | 10 | 77 | 0 |
Quality Earnings: RMDA has a high level of non-cash earnings.
Growing Profit Margin: RMDA's current net profit margins (11.6%) are lower than last year (15.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RMDA's earnings have grown significantly by 22.2% per year over the past 5 years.
Accelerating Growth: RMDA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RMDA had negative earnings growth (-2.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (27.9%).
Return on Equity
High ROE: RMDA's Return on Equity (14.3%) is considered low.